Adverum Biotechnologies Inc  

(Public, NASDAQ:ADVM)   Watch this stock  
Find more results for Paul Wachter
+0.18 (5.90%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.02 - 3.24
52 week 2.99 - 16.73
Open 3.07
Vol / Avg. 352,778.00/192,984.00
Mkt cap 87.63M
P/E     -
Div/yield     -
EPS -2.05
Shares 27.13M
Beta     -
Inst. own 87%
Aug 11, 2016
Q2 2016 Avalanche Biotechnologies Inc Earnings Release (Estimated) Add to calendar
May 6, 2016
Q1 2016 Avalanche Biotechnologies Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -5808.30% -2046.27%
Operating margin -5852.08% -2062.22%
EBITD margin - -1961.49%
Return on average assets -23.87% -22.27%
Return on average equity -24.99% -23.60%
Employees 54 -
CDP Score - -


1035 Obrien Dr
MENLO PARK, CA 94025-1408
United States - Map
+1-650-2726269 (Phone)
+1-650-3621908 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing medicines to patients suffering from chronic or debilitating disease. The Company operates and manages its business in the segment of developing and commercializing gene therapeutics. It focuses on diseases with unmet medical need, including ophthalmic diseases, such as wet age-related macular degeneration (AMD), as well as rare genetic diseases. The Company's product candidates include AVA-101 and AVA-201 for treatment of Wet AMD; AVA-322 and AVA-323 for the treatment of Color Vision Deficiency, and AVA-311 for the treatment of Juvenile X-linked Retinoschisis. It has generated human proof-of-concept data for AVA-101 in a Phase I trial with over eight wet AMD subjects conducted at Lions Eye Institute (LEI) in Australia. It is developing AVA-322 and AVA-323 for the treatment of color vision deficiency (CVD).

Officers and directors

Mark S. Blumenkranz M.D. Chairman of the Board, Co-Founder
Age: 64
Bio & Compensation  - Reuters
Amber Salzman Ph.D. President, Chief Operating Officer, Director
Bio & Compensation  - Reuters
Paul B. Cleveland Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Steven D Schwartz Co-Founder, Director
Age: 53
Bio & Compensation  - Reuters
Leone D. Patterson Chief Financial Officer, Principal Financial Officer
Age: 53
Bio & Compensation  - Reuters
Mehdi Gasmi Ph.D. Chief Technology Officer
Age: 48
Bio & Compensation  - Reuters
Michael C. Swartzburg Principal Accounting Officer
Age: 48
Bio & Compensation  - Reuters
Mitchell Finer Director
Bio & Compensation  - Reuters
John Peter McLaughlin Director
Age: 64
Bio & Compensation  - Reuters
Paul D. Wachter Director
Age: 59
Bio & Compensation  - Reuters